AXIN1 and hepatocellular carcinoma: Overexpression of wild-type AXIN1, but not mutant AXIN1, suppressed the proliferation of HCC cell lines and accelerated their programmed cell death, implicating AXIN1 as a therapeutic target in HCC [29].